FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial

BACKGROUND: FOLFIRI [irinotecan, folinic acid (CF), and fluorouracil] is considered a standard second-line chemotherapy regimen for patients with metastatic colorectal cancer (mCRC) who failed first-line XELOX/FOLFOX regimens. However, it remains unknown whether fluorouracil is still necessary in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaowei, Duan, Ran, Wang, Yusheng, Liu, Xin, Zhang, Wen, Zhu, Xiaodong, Chen, Zhiyu, Shen, Wei, He, Yifu, Wang, Hong Qiang, Huang, Mingzhu, Wang, Chenchen, Zhang, Zhe, Zhao, Xiaoying, Qiu, Lixin, Luo, Jianfeng, Sheng, Xuedan, Guo, Weijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771434/
https://www.ncbi.nlm.nih.gov/pubmed/35069808
http://dx.doi.org/10.1177/17588359211068737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771434/
https://www.ncbi.nlm.nih.gov/pubmed/35069808
http://dx.doi.org/10.1177/17588359211068737

Ejemplares similares